RxDoctor Payments DataLook up a doctor →

Martina Porter, MD

Dermatology · Boston, MANPI 1871931618

Payments from drug & device makers

$1,057,714in general payments, 2019–2025

Across 292 payments — averaging $3622.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$295K
  • Novartis$271K
  • Incyte Corporation$190K
  • AbbVie$100K
  • Sanofi US Services Inc.$73K
  • UCB, Inc.$34K
  • plus $94K from 9 others
$45,513in research payments, 2019–2025

Across 18 payments — averaging $2528.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$22K
  • Novartis Pharma AG$11K
  • Novartis$9K
  • Pfizer$3K

What the payments were for

  • Consulting fees$190,06386%
  • Speaking & faculty fees$18,0028%
  • Travel & lodging$8,8824%
  • Food & beverage$2,9321%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,057,714 in reported general payments places this provider in the 95th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$30,191
Medicare patients
127
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab43$803,500
Cosentyx Sensoready (2 Pens)Secukinumab34$404,878
StelaraUstekinumab14$388,670
Cosentyx Unoready PenSecukinumab16$231,289
TremfyaGuselkumab12$167,315
Taltz AutoinjectorIxekizumab11$134,558
RinvoqUpadacitinib16$126,765
OtezlaApremilast28$108,073
Dupixent SyringeDupilumab19$68,338
Dupixent PenDupilumab13$47,671
Pimecrolimus12$3,805
Calcipotriene12$2,571
Clobetasol Propionate15$533
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc12$429
Ketoconazole28$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$100,391$126,76516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 dermatology providers in Massachusetts.

Other dermatology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →